Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Registration Number
- NCT00051688
- Lead Sponsor
- Chiron Corporation
- Brief Summary
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Cancer Institute Medical Group
🇺🇸Santa Monica, California, United States
ACRC/Arizona Clinical Research Center
🇺🇸Tucson, Arizona, United States
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Kansas City Oncology and Hematology Group
🇺🇸Kansas City, Missouri, United States
Northwestern University Feinberg School of Medicine
🇺🇸Chicago, Illinois, United States
Comprehensive Cancer Centers of the Desert
🇺🇸Palm Springs, California, United States
Georgetown University Medical Center, Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States